Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares derive their revenue from three operating segments.

Namely CSL Behring (the company's blood plasma segment), CSL Vifor, and its Seqirus businesses.

The S&P/ASX 200 Index (ASX: XJO) biotech stock acquired CSL Vifor, a global leader in iron deficiency therapies, in 2022 for US$11.7 billion. Vifor has been struggling to achieve growth over the past two years.

However, with the end of the global pandemic, CSL's Behring division has seen elevated costs come down along with an improving outlook for plasma collections.

Since 2021, CSL has increased both its interim and final dividend every year.

At the current share price of $$279.98, CSL shares trade on a fully franked trailing yield of 1.4%.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Here's what these experts are saying about the Aussie biotech giant.

Why now is a good time to buy CSL shares

Jed Richards, financial advisor at Shaw and Partners, has a 'buy' rating on CSL shares.

According to Richards (courtesy of The Bull), "This well managed blood products company offers compelling long-term tailwinds. CSL is steadily growing its dividend stream."

Richards continues:

The company usually under-promises and over-delivers when it comes to profit. The stock has underperformed on the back of a slower recovery in margins.

Also behind a weaker share price was a phase 3 study which found its CSL112 drug was unable meet its primary efficacy endpoint of reducing the risk of major adverse cardiovascular events in patients at 90 days following a first heart attack.

And with CSL shares down 9% over the past 12 months, Richards believes now could be an opportune time to buy.

"The recent share price presents an attractive entry level for investors," he said.

Emma Fisher, portfolio manager at Airlie Funds Management, is also a fan of the ASX 200 biotech company.

Addressing her investment philosophy more broadly, Fisher said (quoted by The Australian Financial Review):

Investing is not about having epiphanies. It's not lightning-bolt moments in the shower where you realise that some secular megatrend is going to make you all this money. It's about the nuts and bolts – talking to companies, having an open mind, reading widely.

As for CSL shares, she said these "should be in any Aussie portfolio".

How has the ASX 200 biotech stock been tracking?

CSL shares are bucking the wider market sell-down today to be up 0.3% at the time of writing.

As mentioned above, the ASX 200 biotech share is down 9% over the past 12 months.

But in the past months, we have seen a marked uptrend. Since market close on 30 October, shares are up 21%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »